Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

NCT06816914 is registered in ClinicalTrials.gov with Taichung Veterans General Hospital as lead sponsor.

NCT NCT06816914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06816914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
Lead sponsor
Taichung Veterans General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 5, 2025
Completion date
February 5, 2028
Enrollment
84 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

resectable pancreatic adenocarcinoma